AAAAAA
Results: 1-25/71
Authors:
MELICHAR B
SAVARY C
KUDELKA AP
VERSCHRAEGEN C
KAVANAGH JJ
EDWARDS CL
PLATSOUCAS CD
FREEDMAN RS
Citation: B. Melichar et al., LINEAGE-NEGATIVE HUMAN-LEUKOCYTE ANTIGEN-DR+ CELLS WITH THE PHENOTYPEOF UNDIFFERENTIATED DENDRITIC CELLS IN PATIENTS WITH CARCINOMA OF THEABDOMEN AND PELVIS, Clinical cancer research, 4(3), 1998, pp. 799-809
Authors:
MELICHAR B
SAVARY C
KUDELKA AP
VERSCHRAEGEN C
KAVANAGH JJ
EDWARDS CL
PLATSOUCAS CD
FREEDMAN RS
Citation: B. Melichar et al., LINEAGE-NEGATIVE HUMAN-LEUKOCYTE ANTIGEN-DR+ CELLS WITH THE PHENOTYPEOF UNDIFFERENTIATED DENDRITIC CELLS IN PATIENTS WITH CARCINOMA OF THEABDOMEN AND PELVIS, Clinical cancer research, 4(3), 1998, pp. 799-809
Authors:
VERSCHRAEGEN CF
VASURATNA A
EDWARDS C
FREEDMAN R
KUDELKA AP
TORNOS C
KAVANAGH JJ
Citation: Cf. Verschraegen et al., CLINICOPATHOLOGICAL ANALYSIS OF MULLERIAN ADENOSARCOMA - THE M.D.-ANDERSON-CANCER-CENTER EXPERIENCE, Oncology Reports, 5(4), 1998, pp. 939-944
Authors:
KUDELKA AP
VASURATNA A
EDWARDS CL
AUGUSTINE K
BENJAPIBAL M
VERSCHRAEGEN CF
KAVANAGH JJ
Citation: Ap. Kudelka et al., GEMCITABINE AFTER BONE-MARROW TRANSPLANTATION FOR REFRACTORY JUVENILEGRANULOSA-CELL TUMOR, Anti-cancer drugs, 9(7), 1998, pp. 621-623
Authors:
BENJAPIBAL M
KUDELKA AP
VASURATNA A
EDWARDS CL
VERSCHRAEGEN CF
VALERO V
VADHANRAJ S
KAVANAGH JJ
Citation: M. Benjapibal et al., DOCETAXEL AND CYCLOPHOSPHAMIDE-INDUCED REMISSION IN PLATINUM AND PACLITAXEL REFRACTORY OVARIAN-CANCER, Anti-cancer drugs, 9(6), 1998, pp. 577-579
Authors:
KUDELKA AP
HASENBURG A
VERSCHRAEGEN CF
EDWARDS CL
MEYERS CA
VARMA D
FREEDMAN RS
FORMAN A
CONRAD CA
GROVE W
GROTHEY A
KAVANAGH JJ
Citation: Ap. Kudelka et al., PHASE-II STUDY OF IV CL-980 IN PATIENTS WITH ADVANCED PLATINUM REFRACTORY EPITHELIAL OVARIAN-CARCINOMA, Anti-cancer drugs, 9(5), 1998, pp. 405-409
Authors:
VASURATNA A
KUDELKA AP
EDWARDS CL
WOOTIPOOM V
VERSCHRAEGEN CF
CHARNSANGAVEJ C
KAVANAGH JJ
Citation: A. Vasuratna et al., PROLONGED REMISSION OF ENDOMETRIAL CANCER WITH PACLITAXEL AND CARBOPLATIN, Anti-cancer drugs, 9(3), 1998, pp. 283-285
Authors:
VERSCHRAEGEN CF
NATELSON EA
GIOVANELLA BC
KAVANAGH JJ
KUDELKA AP
FREEDMAN RS
EDWARDS CL
ENDE K
STEHLIN JS
Citation: Cf. Verschraegen et al., A PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ORAL 9-NITROCAMPTOTHECIN, A NOVEL WATER-INSOLUBLE TOPOISOMERASE-I INHIBITOR, Anti-cancer drugs, 9(1), 1998, pp. 36-44
Authors:
VERSCHRAEGEN CF
HARRIS N
STEGER M
KAVANAGH JJ
KUDELKA AP
GIOVANELLA B
GUPTA E
Citation: Cf. Verschraegen et al., PHARMACOLOGY STUDY OF MULTIPLE ORAL DOSES OF 9-NITROCAMPTOTHECIN (9NC), Annals of oncology, 9, 1998, pp. 268-268
Authors:
KAVANAGH JJ
VERSCHRAEGEN CF
KUDELKA AP
Citation: Jj. Kavanagh et al., IRINOTECAN IN CERVICAL-CANCER, Oncology, 12(8), 1998, pp. 94-98
Authors:
PARK TK
LEE JP
KIM SN
CHOI SM
KUDELKA AP
KAVANAGH JJ
Citation: Tk. Park et al., INTERFERON-ALPHA-2A, 13-CIS-RETINOIC ACID AND RADIOTHERAPY FOR LOCALLY ADVANCED-CARCINOMA OF THE CERVIX - A PILOT-STUDY, European journal of gynaecological oncology, 19(1), 1998, pp. 35-38
Authors:
NASH MA
LENZI R
EDWARDS CL
KAVANAGH JJ
KUDELKA AP
VERSCHRAEGEN CF
PLATSOUCAS CD
FREEDMAN RS
Citation: Ma. Nash et al., DIFFERENTIAL EXPRESSION OF CYTOKINE TRANSCRIPTS IN HUMAN EPITHELIAL OVARIAN-CARCINOMA BY SOLID TUMOR SPECIMENS, PERITONEAL-EXUDATE CELLS CONTAINING TUMOR, TUMOR-INFILTRATING LYMPHOCYTE (TIL)-DERIVED T-CELL LINES AND ESTABLISHED TUMOR-CELL LINES, Clinical and experimental immunology, 112(2), 1998, pp. 172-180
A PHASE-I STUDY OF TNP-470 ADMINISTERED TO PATIENTS WITH ADVANCED SQUAMOUS-CELL CANCER OF THE CERVIX
Authors:
KUDELKA AP
LEVY T
VERSCHRAEGEN CF
EDWARDS CL
PIAMSOMBOON S
TERMRUNGRUANGLERT W
FREEDMAN RS
KAPLAN AL
KIEBACK DG
MEYERS CA
JAECKLE KA
LOYER E
STEGER M
MANTE R
MAVLIGIT G
KILLIAN A
TANG RA
GUTTERMAN JU
KAVANAGH JJ
Citation: Ap. Kudelka et al., A PHASE-I STUDY OF TNP-470 ADMINISTERED TO PATIENTS WITH ADVANCED SQUAMOUS-CELL CANCER OF THE CERVIX, Clinical cancer research, 3(9), 1997, pp. 1501-1505
Authors:
SEETALAROM K
KUDELKA AP
VERSCHRAEGEN CF
KAVANAGH JJ
Citation: K. Seetalarom et al., TAXANES IN OVARIAN-CANCER TREATMENT, Current opinion in obstetrics & gynecology, 9(1), 1997, pp. 14-20
Authors:
KUDELKA AP
SIDDIK ZH
TRESUKOSOL D
EDWARDS CL
FREEDMAN RS
MADDEN TL
RASTOGI R
HORD M
KIM EE
TORNOS C
MANTE R
KAVANAGH JJ
Citation: Ap. Kudelka et al., A PHASE-II AND PHARMACOKINETIC STUDY OF ENLOPLATIN IN PATIENTS WITH PLATINUM REFRACTORY ADVANCED OVARIAN-CARCINOMA, Anti-cancer drugs, 8(7), 1997, pp. 649-656
Authors:
KUDELKA AP
WINN R
EDWARDS CL
DOWNEY G
GREENBERG H
DAKHIL SR
FREEDMAN RS
LOCOCO S
UMBREIT J
DELMORE JE
ARBUCK S
LOYER E
GACRAMA P
FUEGER R
KAVANAGH JJ
Citation: Ap. Kudelka et al., AN UPDATE OF A PHASE-II STUDY OF PACLITAXEL IN ADVANCED OR RECURRENT SQUAMOUS-CELL CANCER OF THE CERVIX, Anti-cancer drugs, 8(7), 1997, pp. 657-661
Authors:
TERMRUNGRUANGLERT W
KUDELKA AP
EDWARDS CL
DELCLOS L
VERSCHRAEGEN CF
KAVANAGH JJ
Citation: W. Termrungruanglert et al., GYNECOLOGIC CANCER IN THE ELDERLY, Clinics in geriatric medicine, 13(2), 1997, pp. 363
Authors:
ASHOUR AA
VERSCHRAEGEN CF
KUDELKA AP
KAVANAGH JJ
Citation: Aa. Ashour et al., PARANEOPLASTIC SYNDROMES OF GYNECOLOGIC NEOPLASMS, Journal of clinical oncology, 15(3), 1997, pp. 1272-1282
Authors:
VERSCHRAEGEN CF
LEVY T
KUDELKA AP
LLERENA E
ENDE K
FREEDMAN RS
EDWARDS CL
HORD M
STEGER M
KAPLAN AL
KIEBACK D
FISHMAN A
KAVANAGH JJ
Citation: Cf. Verschraegen et al., PHASE-II STUDY OF IRINOTECAN IN PRIOR CHEMOTHERAPY-TREATED SQUAMOUS-CELL CARCINOMA OF THE CERVIX, Journal of clinical oncology, 15(2), 1997, pp. 625-631
Authors:
PIAMSOMBOON S
KUDELKA AP
TERMRUNGRUANGLERT W
VANBESIEN K
EDWARDS CL
LIFSHITZ S
SCHOMER DF
CHAMPLIN R
MANTE RP
KAVANAGH JJ
VERSCHRAEGEN CF
Citation: S. Piamsomboon et al., REMISSION OF REFRACTORY GESTATIONAL TROPHOBLASTIC DISEASE IN THE BRAIN WITH IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE (ICE) - FIRST REPORT ANDREVIEW OF LITERATURE, European journal of gynaecological oncology, 18(6), 1997, pp. 453-456
Authors:
BALAT O
KUDELKA AP
EDWARDS CL
VERSCHRAEGEN CF
KAVANAGH JJ
Citation: O. Balat et al., PROLONGED REMISSION OF PLATINUM-REFRACTORY OVARIAN-CANCER WITH DOCETAXEL - BRIEF REPORT AND REVIEW OF LITERATURE, European journal of gynaecological oncology, 18(5), 1997, pp. 341-342
PROLONGED ORAL ETOPOSIDE FOR ADVANCED UTERINE LEIOMYOSARCOMA WITH PULMONARY METASTASES - CASE-REPORT
Authors:
TERMRUNGRUANGLERT W
KUDELKA AP
PIAMSOMBOON S
EDWARDS CL
TORNOS C
KAVANAGH JJ
Citation: W. Termrungruanglert et al., PROLONGED ORAL ETOPOSIDE FOR ADVANCED UTERINE LEIOMYOSARCOMA WITH PULMONARY METASTASES - CASE-REPORT, European journal of gynaecological oncology, 18(2), 1997, pp. 97-100
Authors:
GERSON R
SERRANO A
BELLO MDC
LAZARO M
KUDELKA AP
KAVANAGH JJ
Citation: R. Gerson et al., RESPONSE OF CHORIOCARCINOMA TO PACLITAXEL - CASE-REPORT AND REVIEW OFRESISTANCE, European journal of gynaecological oncology, 18(2), 1997, pp. 108-110
Authors:
LLERENA E
KUDELKA AP
TORNOS C
CEDILLO GF
LOPEZ A
EDWARDS CL
LITAM JP
KAVANAGH JJ
Citation: E. Llerena et al., REMISSION OF A CHEMOTHERAPY RESISTANT TUMOR OF LOW MALIGNANT POTENTIAL WITH TAMOXIFEN, European journal of gynaecological oncology, 18(1), 1997, pp. 23-25
Authors:
HERRADA J
KUDELKA AP
TORNOS C
SHIN DM
KAVANAGH JJ
EDWARDS CL
VERSCHRAEGEN CF
Citation: J. Herrada et al., REMISSION WITH CARBOPLATIN OF PACLITAXEL RESISTANT PRIMARY PERITONEALPAPILLARY SEROUS CARCINOMA - CASE-REPORT, European journal of gynaecological oncology, 18(1), 1997, pp. 39-41